Press Releases

Date Title
11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
11/2/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences
10/29/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/27/21 Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
10/13/21 Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
10/12/21 Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021
10/12/21 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
Displaying 21 - 30 of 726